Alice T. Shaw, MD, PhD

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses lorlatinib in the treatment of patients with lung cancer.

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the efficacy of lorlatinib in ALK-positive non–small cell lung cancer.

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the phase III results of the international ALEX trial, which compared the alectinib (Alecensa) with crizotinib (Xalkori) in the frontline setting for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib as first-line therapy in the treatment of patients with lung cancer.

Alice T. Shaw, MD, PhD, thoracic oncologist at the Massachusetts General Hospital Cancer Center, discusses ceritinib in newly diagnosed patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases.

Alice Tsang Shaw, MD, PhD, thoracic oncologist, Massachusetts General Hospital Cancer Center, discusses overcoming resistance to targeted therapy in lung cancer.

Alice T. Shaw, MD, PhD, discusses the two most advanced next-generation ALK-inhibitors for the treatment of non-small cell lung cancer (NSCLC): LDK378 and alectinib (AF802).

Alice T. Shaw, MD, PhD, discusses how crizotinib has changed patient care over the last few years.

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses monitoring adverse events associated with crizotinib when treating patients with ALK-positive lung cancer

Lead author, Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital, reviews the first published results from a randomized phase III trial investigating crizotinib in patients with ALK-positive non-small cell lung cancer.

Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, discusses the clinical activity of the ALK inhibitor LDK378 in patients with non-small cell lung cancer harboring an ALK alteration.